The New England journal of medicine
-
Randomized Controlled Trial
Phase 1 Trial of a Therapeutic Anti-Yellow Fever Virus Human Antibody.
Insufficient vaccine doses and the lack of therapeutic agents for yellow fever put global health at risk, should this virus emerge from sub-Saharan Africa and South America. ⋯ This phase 1 trial of TY014 did not identify worrisome safety signals and suggested potential clinical benefit, which requires further assessment in a phase 2 trial. (Funded by Tysana; ClinicalTrials.gov number, NCT03776786.).